Cancer biology grants

Full proposal stage (by invitation only) for the Crazy 8 Brain Tumor grant targeting pediatric brain tumor research. Open since January 2026; notification in November 2026.

Second call for the Cancer Prevention Graduate School priority programme. Proposals must be submitted in English. Supports cancer prevention research training structures.

Add-on funding for ongoing or recently completed KWF-funded projects (incl. KWF-PPP, TTW Technology for Oncology, KWF-NWO early detection) that have reached at least TRL 3. Supports translational pathway definition, targeted development/validation, and regulatory/implementation preparation. TTO commitment letter mandatory; collaboration with TTO of applicant's research institution required.

Supports bio-therapeutic research impacting children with cancer. Open since April 2026; notification in November 2026.

Accelerator grant supporting childhood cancer research. Open since March 2026; notification in October 2026.

Funds research on childhood cancer. Open since March 2026; notification in November 2026.

Supports late-phase (phase 2/3) international clinical trials focused on radiotherapy or surgery as core experimental interventions for rare cancers (incidence <6/100,000/year) and/or hard-to-treat cancers (5-year survival <25%). Requires partners from at least 3 of 5 funding countries; clinical-trial focus with mandatory patient involvement and quality-of-life assessment plans.

International call by five European cancer charities to accelerate clinical research into local treatment strategies for rare and hard-to-treat cancers. Focuses on improving effective and accessible therapies for patients with limited treatment options.

Supports late-phase (phase 2/3) international clinical trials focused on radiotherapy or surgery as core experimental interventions for rare cancers (incidence <6/100,000/year) and/or hard-to-treat cancers (5-year survival <25%). Proposals must include partners from at least 3 of the 5 funding countries and demonstrate strong rationale for international collaboration, patient involvement, and quality-of-life assessment.

Add-on funding exclusively for ongoing or recently completed KWF projects to strengthen translational relevance of oncology drug development. Supports training, implementation, and validation of advanced preclinical models; outsourcing to academic service providers or CROs is allowed.

Supports academic-led clinical trials (Phase I–III) for new investigational medicinal products targeting cancer with unmet medical needs. Lead institute must be in the Netherlands; public participating parties must be in Europe. Patient involvement required; public-private partnerships allowed. Proposals must be in English.

13th call for translational oncology research projects. Supports bench-to-bedside cancer research. Guidelines available in English; applicants should review 'What to consider before applying' before submitting.

Funds fundamental (Basic) and Credentialing cancer research addressing biological mechanisms of cancer onset, growth, and spread, as well as psychosocial mechanisms. Proposal types include Research Project, Consortium, and Unique High-Risk. Young Investigator Grants must be submitted under a separate YIG call.

Dedicated to basic research uncovering mechanisms driving cancer onset, growth, and spread. Intended for proposals within the Basic research and Credentialing phases. Aims to address knowledge gaps and identify new leads for prevention, diagnosis, and treatment.

Horizon Europe RIA under the EU Cancer Mission supporting development of validated microbiome tools for early cancer prediction before disease onset, including AI risk modelling, longitudinal cohort studies, and comparison with liquid biopsy tests. Proposals must address multiple cancer types where possible and collaborate with large cohorts/registries. Lump sum grant; one grant expected.

Funds development of advanced multiscale Virtual Human Twin (VHT) models for cancer research, focusing on cancers with limited treatment options, rare/paediatric cancers, and refractory cancers. Proposals must integrate AI tools for multimodal FAIR data analysis, validate VHTs with longitudinal patient data, and make assets available via UNCAN.eu and the Advanced VHT Platform. Interdisciplinary consortia including clinicians, patient representatives, AI experts, and SMEs are expected.

Research and Innovation Action under the EU Cancer Mission (HORIZON-MISS-2026-02), with a total budget of €22.186M and 3 indicative grants of €7M–€8M each. Full scope details are in the specific work programme topic description.

Research and Innovation Action under the EU Cancer Mission (HORIZON-MISS-2026-02), with a total budget of €15M and 3 indicative grants of around €5M each. Full scope details are in the specific work programme topic description.

Innovation Action under the EU Cancer Mission (HORIZON-MISS-2026-02), with a total budget of €7M and 1 indicative grant of around €7M. Full scope details are in the specific work programme topic description.